Research Reports

Key takeaways

Net loss increased 10.1% to -$18.3M versus -$16.6M prior year, reflecting higher operating expenses during clinical development.

Diluted EPS improved 16.7% to -$0.10 from -$0.12, driven by operational progress despite share expansion.

Operating cash use rose to -$17.3M from -$13.2M, supporting R&D for product candidates advancing to later clinical stages with higher costs.

Capital expenditures increased to $82K from $18K to support lab facilities and business operations growth.

Company expects cash resources to fund operating expenses and capital needs into 2028 per research and development plans.

Full analysis

Net income was -$18.3 million, 10.1% worse than -$16.6 million year-over-year. Diluted EPS showed improvement at -$0.10, up 16.7% from -$0.12, as the per-share impact lessened amid pipeline progress. Product candidates in later stages of clinical development generally incur higher costs due to larger, longer trials, explaining sustained R&D pressures without specific quarterly breakdowns.

The company periodically reviews investments for other-than-temporary declines, maintaining prudent oversight. These dynamics underscore Compass Therapeutics' focus on clinical milestones, with losses widening as investments ramp but EPS efficiency improving and cash position securing multi-year operations.

CMPX · Compass Therapeutics, Inc.

Summary

Key takeaways

Full analysis